Abstract: An equipment support, such as an IV pole, comprises an upper portion, a lower portion having a lower end configured to engage a socket, and an actuator movable relative to the lower end. When the upper portion is gripped by a releasable gripper, the lower end can be disengaged from the socket by moving the actuator from a first position to a second position. The lower portion can be telescoped relative to the upper portion by moving the actuator from the second position to a third position.

Abstract: A patient support includes a lower frame, an upper frame supported above the lower frame, an equipment carrier coupled to the upper frame, and an actuator operable to adjust the orientation of the equipment carrier to compensate for the upper frame changing its orientation between the Trendelenberg and reverse Trendelenberg positions.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK4. Methods of using these compounds for modulation of MEKK4 expression and for treatment of diseases associated with expression of MEKK4 are provided.

Abstract: Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for diagnosis and treatment of diseases and conditions associated with expression of apolipoprotein B are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TFAP2C. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TFAP2C. Methods of using these compounds for modulation of TFAP2C expression and for treatment of diseases associated with expression of TFAP2C are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of thyroid hormone receptor interactor 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding thyroid hormone receptor interactor 6. Methods of using these compounds for modulation of thyroid hormone receptor interactor 6 expression and for treatment of diseases associated with expression of thyroid hormone receptor interactor 6 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of microsomal triglyceride transfer protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding microsomal triglyceride transfer protein. Methods of using these compounds for modulation of microsomal triglyceride transfer protein expression and for treatment of diseases associated with expression of microsomal triglyceride transfer protein are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interferon gamma receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interferon gamma receptor 2. Methods of using these compounds for modulation of Interferon gamma receptor 2 expression and for treatment of diseases associated with expression of Interferon gamma receptor 2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cholesteryl ester transfer protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cholesteryl ester transfer protein. Methods of using these compounds for modulation of cholesteryl ester transfer protein expression and for treatment of diseases associated with expression of cholesteryl ester transfer protein are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of acyl coenzyme A cholesterol acyltransferase-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding acyl coenzyme A cholesterol acyltransferase-1. Methods of using these compounds for modulation of acyl coenzyme A cholesterol acyltransferase-1 expression and for treatment of diseases associated with expression of acyl coenzyme A cholesterol acyltransferase-1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.

Abstract: An assembly includes a first, second and third components having respective first, second and third holes. The assembly further includes a locating feature assembled into the holes having a small portion and a large portion that provide a shoulder therebetween. The locating feature further includes a fixing portion near the small portion to secure the second component relative to the assembly and a fixing portion near the large portion to secure the third component relative to the assembly. The small portion is located in the second hole to align the locating feature relative to the second component, and the large portion is located in the third hole to align the locating feature relative to the third component. The second component is aligned relative to the third component, and the first component is situated between the second and third components and between the shoulder and the second component.

Abstract: Compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for diagnosis and treatment of disease associated with expression of C-reactive protein are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.

Abstract: An equipment management system provides an equipment support for supporting patient care equipment. The equipment support may be mountable on an arm that extends from a wall, on a column depending from the arm, on a wall mount, on a stand, or on a patient support. Various methods may be used to vertically move the equipment support up and down to engage and disengage the equipment support from supporting devices.

Abstract: Repetitive synchronization in program code is optimized through lock coarsening that is performed subject to a number of constraints. Using a forward pass over the program code followed by a backward pass, region extent bits may be determined that identify the points in the program where object locking can be coarsened. The program code may then be modified to realize coarsened locking regions determined based on the region extent bits. Alternatively, previously determined value numbers may provide much of the information collected by the two passes. In such a case, a single pass over the program code may locate features that limit lock coarsening opportunities. A set of synchronization operations that can be removed may then be determined and used when modifying the program code to coarsen locking regions.

Abstract: In preparing inlined program code for compiling, a synchronization depth is recorded in a table for ranges of program counter addresses. Furthermore, a stack frame is dedicated for the recordation of references to objects locked during the execution of the code. Such references are recorded in the stack frame at a location based on synchronization depth. When an exception occurs, the synchronization depth may be determined from the table and used to obtain, from the stack frame, a reference to an object from which a lock should be removed.

Abstract: Method of separating molecules by providing a cross-linked polymer gel having a cross-linking moiety of the formula wherein X, X′, Y, Z and R2 are as defined in the specification. A sample containing the molecules to be separated is placed on the gel, and the gel is subjected to a separation technique.